Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Children 2 to 9 Years of Age
Phase of Trial: Phase III
Latest Information Update: 26 Jul 2018
At a glance
- Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary)
- Indications Meningococcal meningitis
- Focus Pharmacodynamics
- Sponsors sanofi pasteur
- 19 Jul 2018 Status changed from active, no longer recruiting to completed.
- 29 Sep 2017 Planned End Date changed from 11 Oct 2017 to 13 Oct 2017.
- 29 Sep 2017 Planned primary completion date changed from 11 Oct 2017 to 13 Oct 2017.